Denali Capital Acquisition CORP Form 4 insider transactions

Scilex Holding Co. has distributed a stock dividend of Semnur Pharmaceuticals, Inc. common stock to its shareholders and holders of warrants and convertible notes.

Scilex Holding Co and Scilex, Inc. sold 12.5 million Semnur shares for $200 million, paid in Bitcoin.

Denali Capital Acquisition Corp. announced a $20 million private investment in public equity (PIPE) financing to support its planned business combination with Semnur Pharmaceuticals, Inc.

Denali Capital Acquisition Corp. extended its deadline to complete a business combination by one month to September 11, 2025, by depositing $874.78 into its Trust Account.

Denali Capital Acquisition Corp. has amended its merger agreement with Semnur Pharmaceuticals, Inc. to allow for the issuance of additional Semnur shares prior to closing, primarily for potential private placement financing and advisor compensation.

Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month to August 11, 2025, through a $874.78 deposit into its Trust Account.

Denali Capital Acquisition Corp. extends its business combination deadline to June 11, 2025, by depositing $874.78 into its trust account.

Denali Capital Acquisition Corp. receives notification of delisting from Nasdaq due to failure to meet minimum Market Value of Listed Securities, Total Assets, and Public Float requirements.

Denali Capital Acquisition Corp. extends its business combination deadline to April 11, 2025, by depositing $15,063.74 into its trust account.

Denali Capital Acquisition Corp. extends its business combination deadline to March 11, 2025, by depositing $15,063.74 into its trust account.

Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month, depositing $15,063.74 into its trust account.

Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month, until January 11, 2025, by depositing $15,063.74 into its trust account.

Denali Capital Acquisition Corp. extends its business combination deadline to December 11, 2024, by depositing $15,063.74 into its trust account.

Denali Capital Acquisition Corp. extends its business combination deadline to November 11, 2024, by depositing $15,063.74 into its trust account.

Denali Capital Acquisition Corp. received a Nasdaq notice for failing to meet minimum Market Value of Listed Securities (MVLS) and total assets requirements, granting them until March 31, 2025, to regain compliance.

Denali Capital Global Investments LLC sold 500,000 Class B ordinary shares of Denali Capital Acquisition Corp. to Scilex Holding Company as part of a Sponsor Interest Purchase Agreement.

Jiandong Xu, a director of Denali Capital Acquisition Corp., sold 500,000 Class B ordinary shares to Scilex Holding Company as part of a Sponsor Interest Purchase Agreement related to a merger.

Denali Capital Acquisition Corp. extends its business combination deadline to October 11, 2024, by depositing $15,063.74 into its trust account.

Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, have signed a merger agreement valuing Semnur at $2.5 billion, aiming to create a publicly traded biopharma company.

Denali Capital Acquisition Corp. secures a one-month extension for its business combination deadline by depositing funds into its trust account, financed through a convertible promissory note from Scilex Holding Company.

Denali Capital Acquisition Corp. received shareholder approval to extend the deadline for completing a business combination from July 11, 2024, to April 11, 2025, funded by a convertible promissory note.